8-K: Athira Pharma Completes Enrollment in Key Alzheimer's Trial, Advances ALS Program

Athira Pharma reports full year 2023 financial results, completes enrollment in a Phase 2/3 Alzheimer's trial, and is on track to initiate a first-in-human study for ALS treatment.

Summary

• Athira Pharma has announced its financial results for the year ended December 31, 2023, alongside updates on its clinical pipeline.
• The company completed enrollment in its Phase 2/3 LIFT-AD clinical trial for fosgonimeton, involving approximately 315 patients with mild-to-moderate Alzheimer's disease, with topline data expected in the second half of 2024.
• Athira is also on track to initiate first-in-human studies for ATH-1105, a potential treatment for amyotrophic lateral sclerosis (ALS), in the first half of 2024.
• The company's cash, cash equivalents, and investments totaled $147.4 million as of December 31, 2023, compared to $245.2 million the previous year.
• Research and development expenses increased to $93.8 million in 2023 from $61.5 million in 2022, primarily due to increased clinical trial and manufacturing activities.
• The net loss for 2023 was $117.7 million, or $3.09 per share, compared to a net loss of $95.6 million, or $2.53 per share, in 2022.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the completion of enrollment in the LIFT-AD trial and the progress of ATH-1105, but tempered by the significant net loss and cash burn. The company is making progress, but faces financial challenges.

Positives

• The completion of enrollment in the LIFT-AD trial is a significant milestone for the company's Alzheimer's program.
• The advancement of ATH-1105 into first-in-human studies represents progress in the company's ALS program.
• The strong cash position provides financial stability to support ongoing clinical development.
• The high enrollment rate in the OLEX trial suggests patient interest and potential long-term benefits of fosgonimeton.
• Preclinical data supports the potential of both fosgonimeton and ATH-1105 in treating neurodegenerative diseases.

Negatives

• The company experienced a significant net loss of $117.7 million in 2023.
• Cash reserves decreased from $245.2 million to $147.4 million year-over-year.
• Research and development expenses increased substantially, reflecting the high cost of clinical trials.
• The primary endpoint of the SHAPE trial for Parkinson's disease dementia and dementia with Lewy bodies was not met by protocoled analysis.

Risks

• Clinical trial data may not support the safety, efficacy, and tolerability of Athira's drug candidates.
• Development of drug candidates may be delayed or cease.
• Regulatory authorities could object to protocols, amendments, and other submissions.
• The company may not be able to recruit sufficient patients for its clinical trials.
• There are risks associated with legal proceedings and potential negative interactions of Athira's drug candidates with other treatments.
• The company's assumptions regarding its financial condition and the sufficiency of its cash may be incorrect.
• Adverse conditions in the general domestic and global economic markets could impact the company.
• The impact of competition and new or changing laws and regulations could affect the company's prospects.

Future Outlook

Athira expects to report topline data from the LIFT-AD trial in the second half of 2024 and initiate first-in-human studies of ATH-1105 in the first half of 2024. The company believes its strong balance sheet will support the ongoing advancement of its pipeline through key inflection points.

Management Comments

• We've made important progress in our pursuit to advance potential new treatment options for neurodegenerative diseases, stated Mark Litton, Ph.D., President and Chief Executive Officer of Athira.
• We are encouraged by results shown to date, which we believe support fosgonimetons potential to deliver a first-in-class therapy to Alzheimers disease patients and expect to report topline data from LIFT-AD in the second half of 2024.
• Additionally, we are excited to advance ATH-1105 for the potential treatment of ALS and remain on-track to initiate the first-in-human study in the first half of 2024.
• We ended 2023 with a strong balance sheet that we believe will support the ongoing advancement of our pipeline, including fosgonimeton and ATH-1105, through key inflection points.

Industry Context

The announcement comes amid growing interest and investment in treatments for neurodegenerative diseases like Alzheimer's and ALS. The completion of enrollment in the LIFT-AD trial and the progress of ATH-1105 are significant steps in this competitive landscape. The company's focus on the HGF system represents a novel approach to addressing these conditions.

Comparison to Industry Standards

• The LIFT-AD trial, with approximately 315 patients, is a substantial study in the Alzheimer's space, comparable to other Phase 2/3 trials by companies like Biogen and Eisai with their drug lecanemab.
• The focus on a once-daily, subcutaneously administered drug like fosgonimeton aligns with the industry trend towards more convenient treatment options.
• The development of ATH-1105 for ALS is in line with the industry's efforts to find new treatments for this devastating disease, with companies like Amylyx Pharmaceuticals recently gaining approval for their drug Relyvrio.
• The company's cash burn of approximately $100 million in 2023 is within the range of other clinical-stage biotech companies, but the decrease in cash reserves highlights the need for successful clinical trial outcomes and potential future funding.

Management Changes

Legal Proceedings

• In February 2023, the Company reached an agreement in principle to resolve all claims in the Company's securities class action lawsuit, agreeing to make a one-time payment of $10.0 million.

Stakeholder Impact

• Shareholders: The company's progress in clinical trials and pipeline development is positive, but the net loss and cash burn are concerning.
• Employees: The company's growth and development activities may provide opportunities for career advancement.
• Patients: The company's drug candidates have the potential to provide new treatment options for neurodegenerative diseases.
• Creditors: The company's financial stability is supported by its cash reserves, but the net loss and cash burn are risks.

Next Steps

• Report topline data from the Phase 2/3 LIFT-AD clinical trial in the second half of 2024.
• Initiate first-in-human studies of ATH-1105 for the treatment of ALS in the first half of 2024.
• Present clinical and preclinical data at the 18th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2024) in March 2024.
• Continue the open-label extension (OLEX) trial for fosgonimeton.

Key Dates

Keywords

Alzheimer's disease, amyotrophic lateral sclerosis, fosgonimeton, ATH-1105, neurodegenerative diseases, clinical trials, biopharmaceutical, HGF system, Parkinson's disease, dementia